Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Vascular Endothelial Growth Factor D" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A vascular endothelial growth factor that specifically binds to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 and VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3. In addition to being an angiogenic factor it can act on LYMPHATIC VESSELS to stimulate LYMPHANGIOGENESIS. It is similar in structure to VASCULAR ENDOTHELIAL GROWTH FACTOR C in that they both contain N- and C-terminal extensions that were not found in other VEGF family members.
Use of VEGF-C to prevent restenosis
InactiveUS6958147B1Easy to usePrevent restenosisBiocidePeptide/protein ingredientsVascular Endothelial Growth Factor DPercent Diameter Stenosis
The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and / or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
Owner:VEGENICS PTY LTD
Use of VEGF-C or VEGF-D gene or protein to prevent restenosis
InactiveUS20050256075A1Prevent restenosisReduce amount/severityBiocidePeptide/protein ingredientsRestenosisVascular Endothelial Growth Factor D
The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and / or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
Owner:VEGENICS PTY LTD
Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
InactiveUS20020127222A1Increase acceptanceGood treatment effectPeptide/protein ingredientsAntibody mimetics/scaffoldsAbnormal tissue growthDisease
This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.
Owner:VEGENICS PTY LTD
Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use
InactiveUS7122654B2Promote blood circulationImprove in gaseous exchangeFungiSenses disorderBlood vesselAntagonist
VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
Owner:VEGENICS PTY LTD
Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
ActiveUS20110065176A1Improve abilitiesBacteriaPeptide/protein ingredientsMonoclonal antibodyAngiogenesis growth factor
The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.
Owner:PHARMABCINE
Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
InactiveUS7534572B2Inhibit bindingMaintain integrityPeptide/protein ingredientsBiological material analysisAbnormal tissue growthLymphatic Spread
A method for treating and alleviating disease characterized by the expression of VEGF-D involving screening to find an organism with tumor cells expressing VEGF-D and administering an effective amount of a VEGF-D antagonist; a method for screening for neoplastic diseas, where detection of VEGF-D on or in a sample such as tumor cells, blood vessel endothelial cells or lymph vessel endothelial cells indicates neoplastic disease; a method for promoting and maintaining vascularization of normal tissue in an organism involving administering a vascularization promoting amount of VEGF-D or a fragment or analog thereof to the organism; a method for screening tumors for metastatic risk involving detecting expression of VEFG-D by a tumor which indicates metastatic risk; and a method of detecting micro-metastasis of neoplastic disease involving detection of VEGF-D on or in a tissue sample which indicates metastasis of a neoplastic disease.
Owner:VEGENICS PTY LTD
Topical administration of therapeutic agents and oligonucleotide formulations
Aspects of the invention relate to topical and ocular formulations of spherical nucleic acids (SNA), as well as methods of use thereof and compositions thereof. The formulations may include an inhibitor such as an inhibitor of tumour necrosis factor alpha (TNFa), platelet-derived growth factor subunit A (PDGFA), platelet-derived growth factor subunit B (PDGFB), platelet-derived growth factor subunit C (PDGFC), platelet-derived growth factor subunit D (PDGFD), platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), platelet-derived growth factor receptor like (PDGFRL), vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), vascular endothelial growth factor C (VEGFC) vascular endothelial growth factor D (VEGFD), vascular endothelial growth factor receptor-1 (VEGFR1), vascular endothelial growth factor receptor-2 (VEGFR2), vascular endothelial growth factor receptor-3 (VEGFR3), beta-2 adrenergic receptor (ADRB2), connective tissue growth factor (CTGF), interleukin 1 beta (IL1 β), interleukin 1 receptor-1 (IL1 R1), interleukin 1 receptor-2 (IL1R2), and interleukin 1 receptor-3 (IL1R3). Aspects of the invention further relate to nanostructures comprising self-assembling therapeutic oligonucleotides, such as antisense oligonucleotides, that are linked to a molecular species, wherein the molecular species is positioned in a core of the nanostructure and the oligonucleotides extend radially from the core.
Owner:EXICURE INC
Vascular Endothelial Growth Factor D(VEGF-D) Antibodies and Vectors, and Methods of Uses
InactiveUS20070298493A1Retain biological activityPromote generationSenses disorderFungiBlood vesselAntagonist
VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
Owner:VEGENICS PTY LTD
Autologous Lymph Node Transfer In Combination With VEGF-C Or VEGF-D Growth Factor Therapy to Treat Lymphedema And To Improve Reconstructive Surgery
ActiveUS20140087002A1Conducive to survivalPromote healingPeptide/protein ingredientsSurgical drugsFactor iiVascular Endothelial Growth Factor D
Materials and methods are provided to improve survival of lymph nodes and integration of lymph nodes into a lymphatic network, following lymph node transplantation. The treatment or prevention of lymphedema is also addressed. A method of lymph node transfer includes transferring or transplanting a lymph node or lymph node fragment in a mammalian subject; and administering a composition comprising an agent selected from the group consisting of Vascular Endothelial Growth Factor C (VEGF-C) polynucleotides, VEGF-C polypeptides, Vascular Endothelial Growth Factor D (VEGF-D) polynucleotides, and VEGF-D polypeptides to a perinodal site within 20 cm of the lymph node or lymph node fragment. In certain embodiments, the agent is present in the composition in an amount effective to promote survival of the lymph node and integration of the lymph node into a lymphatic network in the mammalian subject, at the site of transfer or transplantation.
Owner:LAURANTIS PHARMA
Vascular endothelial growth factor d(vegf-d) antibodies and vectors, and methods of uses
InactiveUS20080070831A1Retain biological activityPromote generationOrganic active ingredientsFungiBlood vesselAntagonist
VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.
Owner:VEGENICS PTY LTD
Materials and Methods for the Treatment of Hypertension
InactiveUS20120141424A1Increase stringencyFacilitate and promote expressionBiocidePeptide/protein ingredientsHypertension medicationsVascular Endothelial Growth Factor D
The present invention is directed to materials and methods for the treatment of hypertension and ischemia comprising administering at least one therapeutic agent selected from the group consisting of vascular endothelial growth factor-C product and vascular endothelial growth factor-D product, and optionally, when treating hypertension, a standard of care anti-hypertensive agent.
Owner:VEGENICS PTY LTD
Vascular endothelial growth factor specifically combined with collagen and application thereof
The invention discloses a vascular endothelial growth factor specifically combined with collagen and an application thereof. The vascular endothelial growth factor specifically combined with collagen is a recombination protein obtained by fusing a collagen combination domain with the amino terminal or carboxyl terminal of the vascular endothelial growth factor by connecting peptide; and the aminoacid sequence of the collagen combination domain is the sequence 2 in a sequence list from the amino terminal position 178 to position 184. The invention also discloses an encoding gene of the vascular endothelial growth factor specifically combined with the collagen. The vascular endothelial growth factor specifically combined with the collagen is favorable for solving the problems of low activity and high risk caused by the indiffusion of the vascular endothelial growth factor, and provides a new method for repairing myocardial damage.
Owner:YANTAI ZHENGHAI BIO TECH +1
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Angiopoietin-related protein 3, Soluble Lymphatic vessel endothelial hyaluronic acid receptor 1, and Vascular endothelial growth factor D as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL
Application of collagen targeted vascular endothelial growth factors in old myocardial infarction treatment
InactiveCN109125710AAvoid degradationFunction increasePeptide/protein ingredientsCardiovascular disorderSide effectFactor ii
The invention discloses application of collagen targeted vascular endothelial growth factors in old myocardial infarction treatment. In the application, the collagen targeted vascular endothelial growth factors are fused proteins obtained by fusing collagen binding regions at the ends N and / or C of the vascular endothelial growth factors, the vascular endothelial growth factors are proteins shownfrom the first site to the 166th site with the amino acid sequence of SEQ ID No.1, and the collagen binding regions are proteins shown from the 178th site to the 184th site with the amino acid sequence of SEQ ID No.1. It is shown through experiments that the collagen targeted vascular endothelial growth factors have the capacity of being combined with a cell epimatrix and can be specifically combined with an ischemia cardiomyocyte epimatrix, the myocardial ischemic injury repairing effect is improved, the side effects of VEGF high-dosage medicine application can be avoided, and the collagen targeted vascular endothelial growth factors can be used for treating the old myocardial infarction.
Owner:INST OF GENETICS & DEVELOPMENTAL BIOLOGY CHINESE ACAD OF SCI
Use of VEGF-C or VEGF-D gene or protein to prevent resitenosis
InactiveCN1338943AOrganic active ingredientsPeptide/protein ingredientsPercent Diameter StenosisVascular Endothelial Growth Factor D
The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and / or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
Owner:LUDWIG INST FOR CANCER RES +2
Vegf-d/vegfr2/3-mediated regulation of dendrites
InactiveUS20120308554A1Increased complexityIncrease the lengthNervous disorderPeptide/protein ingredientsDiseaseMedicine
The present invention relates to methods for modulating, i.e. increasing or decreasing, the length and / or the complexity of the dendrites of a neuronal cell by influencing the amount of vascular endothelial growth factor D (VEGFD)-related signaling. The present invention further relates to methods for treating age- and / or disease-related cognitive dysfunctions, or for impairing the memory of a subject. Finally, the present invention relates to recombinant VEGFD (rVEGFD) for use in the treatment of age- and / or disease-related cognitive dysfunctions.
Owner:UNIVERSITY OF HEIDELBERG
Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
ActiveUS8852936B2Promote healingReduce edemaPeptide/protein ingredientsSurgical drugsImproved survivalVascular Endothelial Growth Factor D
Materials and methods are provided to improve survival of lymph nodes and integration of lymph nodes into a lymphatic network, following lymph node transplantation. The treatment or prevention of lymphedema is also addressed. A method of lymph node transfer includes transferring or transplanting a lymph node or lymph node fragment in a mammalian subject; and administering a composition comprising an agent selected from the group consisting of Vascular Endothelial Growth Factor C (VEGF-C) polynucleotides, VEGF-C polypeptides, Vascular Endothelial Growth Factor D (VEGF-D) polynucleotides, and VEGF-D polypeptides to a perinodal site within 20 cm of the lymph node or lymph node fragment. In certain embodiments, the agent is present in the composition in an amount effective to promote survival of the lymph node and integration of the lymph node into a lymphatic network in the mammalian subject, at the site of transfer or transplantation.
Owner:LAURANTIS PHARMA
Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
InactiveUS7601341B2Avoid spreadingInhibiting vascularizationPeptide/protein ingredientsAntibody mimetics/scaffoldsGeloninAbnormal tissue growth
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
InactiveUS20050202015A1Maintain integrityStimulate endothelial cell proliferationPeptide/protein ingredientsBiological material analysisAbnormal tissue growthLymphatic Spread
A method for treating and alleviating disease characterized by the expression of VEGF-D involving screening to find an organism with tumor cells expressing VEGF-D and administering an effective amount of a VEGF-D antagonist; a method for screening for neoplastic diseas, where detection of VEGF-D on or in a sample such as tumor cells, blood vessel endothelial cells or lymph vessel endothelial cells indicates neoplastic disease; a method for promoting and maintaining vascularization of normal tissue in an organism involving administering a vascularization promoting amount of VEGF-D or a fragment or analog thereof to the organism; a method for screening tumors for metastatic risk involving detecting expression of VEFG-D by a tumor which indicates metastatic risk; and a method of detecting micro-metastasis of neoplastic disease involving detection of VEGF-D on or in a tissue sample which indicates metastasis of a neoplastic disease.
Owner:VEGENICS PTY LTD
Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
ActiveUS8927511B2Modulate its functionSenses disorderNervous disorderDiseaseVascular Endothelial Growth Factor D
Oligonucleotide compounds modulate expression and / or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.
Owner:CURNA INC
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
InactiveUS20130330752A1Eliminate needDisease diagnosisBiological testingVascular Endothelial Growth Factor DRenal Failures
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Angiopoietin-related protein 3, Soluble Lymphatic vessel endothelial hyaluronic acid receptor 1, and Vascular endothelial growth factor D as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL
Hybrid chimera polypeptides as dual inhibitors of vascular endothelial growth factor receptor and platelet-derived growth factor receptor
Polypeptides comprising hybrid VEGF and PDGF sequences are provided. The polypeptides are useful in inhibition of angiogenesis and treatment of diseases characterized by pathologic neovascularization.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
ActiveUS20140275488A1Improve abilitiesPeptide/protein ingredientsAntibody mimetics/scaffoldsAngiogenesis growth factorMonoclonal antibody
The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.
Owner:PHARMABCINE
Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
InactiveUS20110059890A1Easy to makeEasy to testPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseMelanoma
This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.
Owner:VEGENICS PTY LTD
Synthetic microrna mimics
PendingCN113227375AOrganic active ingredientsMaterial analysisBlood vesselEndothelial Growth Factors
The present invention relates to the treatment of cardiovascular diseases. In particular the present invention relates to micro RNA (mi RNA) molecules for use in the regulation of the gene expression of Vascular endothelial growth factor A (VEGFA), Vascular endothelial growth factor D (VEGFD) and / or Hypoxia-inducible factor 1-alpha (HIF1A) in a variety of applications, including use in therapeutic and diagnostic applications. VEGFA has diverse functions in both developing and mature individuals. VEGFA is a well-known critical regulator of angiogenesis and is also involved in the development and metastasizing of cancer.
Owner:原住民股份有限公司
Synthetic microrna mimics
PendingUS20220186228A1Reduced expression levelBiological testingDNA/RNA fragmentationBlood vesselEndothelial Growth Factors
The present invention relates to the treatment of cardiovascular diseases. In particular the present invention relates to micro RNA (mi RNA) molecules for use in the regulation of the gene expression of Vascular endothelial growth factor A (VEGFA), Vascular endothelial growth factor D (VEGFD) and / or Hypoxia-inducible factor 1-alpha (HIF1A) in a variety of applications, including use in therapeutic and diagnostic applications. VEGFA has diverse functions in both developing and mature individuals. VEGFA is a well-known critical regulator of angiogenesis and is also involved in the development and metastasizing of cancer.
Owner:RNATIVES INC
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
ActiveUS9758575B2Senses disorderImmunoglobulins against growth factorsAngiogenesis growth factorVascular Endothelial Growth Factor D
Disclosed herein are antibodies capable of inhibiting canine vascular endothelial growth factor and uses thereof in treating a canine angiogenesis-related disorder such as a proliferative disease.
Owner:YUNG SHIN PHARMACEUTICALS INDUSTRIAL CO LTD
VEGF-D (vascular endothelial growth factor-D) monoclonal antibody and kit
InactiveCN108794629AHigh affinityStrong specificityBiological material analysisImmunoglobulins against growth factorsProtein detectionDrug biological activity
The invention discloses a VEGF-D (vascular endothelial growth factor-D) monoclonal antibody. The amino acid sequence of a heavy chain of the VEGF-D monoclonal antibody is as shown in VH:BAA24264, andthe amino acid sequence of a light chain of the VEGF-D monoclonal antibody is as shown in VL:XP_009304362. The VEGF-D monoclonal antibody has high affinity, strong specificity and good biological activity in vitro. A VEGF-D protein detection kit built by the VEGF-D monoclonal antibody and a VEGF-D polyclonal antibody can serve as an index for evaluating tumor lymphangiogenesis and lymphatic metastasis.
Owner:浙江众意生物科技有限公司
Use of VEGF-D gene to prevent restenosis
InactiveUS8455453B2Prevent restenosisReduce amount/severityBiocidePeptide/protein ingredientsPercent Diameter StenosisVascular Endothelial Growth Factor D
The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and / or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins.
Owner:VEGENICS PTY LTD
Vascular endothelial growth factor-d (VEGF)-d and functionally fragments thereof for bone repairing
InactiveUS20090214495A1Reduce the possibilityOrganic active ingredientsBiocideVascular Endothelial Growth Factor DEndothelial NOS
The invention refers to use of VEGF-D or fragments thereof for the preparation of a medicament for therapy and / or prevention of bone diseases, to compositions comprising the same, vectors for gene therapy, to cells expressing VEGF-D.
Owner:UNIV DEGLI STUDI DE SIENA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com